The Need for Academic and Community Collaboration With CAR T-Cell Therapy: Bijal Shah, MD; Michael Wang, MD

Video

The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

This content originally appeared on our sister site, OncLive.

OncLive spoke withBijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, and Michael Wang, MD, professor, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, to learn more about the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

The hematologists explained how integrating primary care physicians into the post–CAR T-cell therapy management of patients with hematologic malignancies is difficul and engaging community practices has not been a priority in many cases. However, integrating primary care physicians is important because they can closely monitor heart function and recovery of immunoglobulin while supporting the patient.

Gaps in communication still exist, particularly when patients come into the emergency room with CAR T-cell therapy–related complications, such as infections. Moreover, these gaps have been further exacerbated with the onset of the COVID-19 pandemic, Wang says.

Aggressive treatments with vaccines, IVIG, and prophylactic antibodies for patients who develop infections after CAR T-cell therapy are helpful, but managing patients who develop CAR T-cell therapy–related complications away from the center in which they received CAR T-cell therapy is challenging. Furthermore, this underscores the need for close collaborations and partnerships between academic and community practices, Shah concludes.

Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.